Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
April 3, 2019
Soleno Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
REDWOOD CITY, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of ...
April 3, 2019
TYME Secures Capital to Advance Pivotal Studies of SM-88 in Metastatic Pancreatic Cancer
NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), announced the closing of ...
April 3, 2019
Gina DiGuglielmo Joins Relmada as Vice President and Head of Clinical Operations
NEW YORK, April 3, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, ...
April 3, 2019
Actinium Highlights Actimab-A and Venetoclax Synergies Observed in New Studies Presented at AACR
NEW YORK, April 3, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) highlighted data from its poster presentation at the AACR or American Association ...
April 3, 2019
Sierra Reports Late-Breaking SRA141 Preclinical Data in Poster at AACR 2019
VANCOUVER , April 3, 2019 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment ...
April 3, 2019
Catalyst Biosciences to Present at The Needham & Company 18th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer, will present ...
April 3, 2019
Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT002, Nasal Naltrexone, for Treatment of Alcohol Use Disorder
SANTA MONICA, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today ...
April 3, 2019
Arena Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 10
SAN DIEGO, April 3, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will ...
April 3, 2019
Checkpoint Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization ...
April 3, 2019
Y-mAbs Therapeutics To Present At The H.C. Wainwright Global Life Sciences Conference in London
NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development ...
April 3, 2019
Chiasma Announces Closing of $34.5 Million Offering of Common Stock and Full Exercise of Underwriters’ Option
WALTHAM, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and ...
April 3, 2019
Lipocine Seeks Injunction Against the Marketing of Clarus Therapeutics' JATENZO® for Testosterone Replacement Therapy
SALT LAKE CITY, April 3, 2019 /PRNewswire/ -- Lipocine Inc.(LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has filed ...
March 27, 2019
Orchard Therapeutics Presents New Registrational Data Demonstrating Sustained Clinical Benefit of OTL-200 for the Treatment of MLD
BOSTON and LONDON, March 27, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with ...
March 27, 2019
DURECT Announces Patient Enrollment in Phase 1b Clinical Trial of Oral DUR-928 in Patients with Non-Alcoholic Steatohepatitis (NASH)
CUPERTINO, Calif., March 27, 2019 /PRNewswire/ -- DURECT Corporation (DRRX) today announced it has commenced patient enrollment in a Phase 1b trial with oral DUR-928 ...
March 27, 2019
Urovant Sciences Initiates Phase 3 Clinical Program with Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)-- Urovant Sciences (UROV), a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for urologic conditions, today announced that it ...
March 27, 2019
Lipocine Announces ABPM Labeling Study Results Consistent with Recently Approved Testosterone Replacement Therapy
SALT LAKE CITY, March 27, 2019 /PRNewswire/ -- Lipocine Inc.(LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced findings from the Ambulatory ...
March 27, 2019
CymaBay Therapeutics Announces Multiple Presentations During The International Liver Conference™ 2019
NEWARK, Calif., March 27, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), today announced that multiple seladelpar presentations will be delivered during The International Liver ...
March 27, 2019
Clinical Outcomes Data on SkinTE™ from Lower Extremity Chronic Wounds to be Presented at Diabetic Limb Salvage (DLS) Conference
SALT LAKE CITY, March 27, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that two ...
March 27, 2019
TRACON Pharmaceuticals Announces TRC105, TRC253 and TRC102 Data Presentations at Upcoming AACR Annual Meeting
SAN DIEGO, March 27, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
March 27, 2019
Albireo to Present Clinical Data on A4250 in Alagille Syndrome and Biliary Atresia at The International Liver Congress™ 2019
BOSTON, March 27, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...
Page 33 of 169